請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47032完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 江伯倫(Bor-Luen Chiang) | |
| dc.contributor.author | Yun-Ying Lee | en |
| dc.contributor.author | 李昀穎 | zh_TW |
| dc.date.accessioned | 2021-06-15T05:45:43Z | - |
| dc.date.available | 2015-09-09 | |
| dc.date.copyright | 2010-09-09 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-08-19 | |
| dc.identifier.citation | AbuBakar, S., Chee, H.Y., Al-Kobaisi, M.F., Xiaoshan, J., Chua, K.B., and Lam, S.K. (1999). Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 61, 1-9.
Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and innate immunity. Cell 124, 783-801. Alexander, J.P., Jr., Baden, L., Pallansch, M.A., and Anderson, L.J. (1994). Enterovirus 71 infections and neurologic disease--United States, 1977-1991. J Infect Dis 169, 905-908. Berger, A. (2000). Th1 and Th2 responses: what are they? BMJ 321, 424. Bible, J.M., Pantelidis, P., Chan, P.K., and Tong, C.Y. (2007). Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 17, 371-379. Blomberg, J., Kahlmeter, O., Lycke, E., and Strannegard, O. (1974). [Findings of viruses among foreign adopted children]. Lakartidningen 71, 3513 passim. Bouslama, L., Nasri, D., Chollet, L., Belguith, K., Bourlet, T., Aouni, M., Pozzetto, B., and Pillet, S. (2007). Natural recombination event within the capsid genomic region leading to a chimeric strain of human enterovirus B. J Virol 81, 8944-8952. Brown, B.A., Oberste, M.S., Alexander, J.P., Jr., Kennett, M.L., and Pallansch, M.A. (1999). Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73, 9969-9975. Brown, B.A., and Pallansch, M.A. (1995). Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 39, 195-205. Chang, G.H., Luo, Y.J., Wu, X.Y., Si, B.Y., Lin, L., and Zhu, Q.Y. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 7, 106. Chang, L.Y., Hsiung, C.A., Lu, C.Y., Lin, T.Y., Huang, F.Y., Lai, Y.H., Chiang, Y.P., Chiang, B.L., Lee, C.Y., and Huang, L.M. (2006). Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 60, 466-471. Chang, L.Y., Huang, Y.C., and Lin, T.Y. (1998). Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 352, 367-368. Chang, L.Y., Lin, T.Y., Huang, Y.C., Tsao, K.C., Shih, S.R., Kuo, M.L., Ning, H.C., Chung, P.W., and Kang, C.M. (1999). Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18, 1092-1096. Chen, S.C., Chang, H.L., Yan, T.R., Cheng, Y.T., and Chen, K.T. (2007). An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg 77, 188-191. Chonmaitree, T., Menegus, M.A., Schervish-Swierkosz, E.M., and Schwalenstocker, E. (1981). Enterovirus 71 infection: report of an outbreak with two cases of paralysis and a review of the literature. Pediatrics 67, 489-493. Chow, M., and Baltimore, D. (1982). Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats. Proc Natl Acad Sci U S A 79, 7518-7521. Chung, Y.C., Huang, J.H., Lai, C.W., Sheng, H.C., Shih, S.R., Ho, M.S., and Hu, Y.C. (2006). Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12, 921-927. Cooper, C.L., Davis, H.L., Morris, M.L., Efler, S.M., Adhami, M.A., Krieg, A.M., Cameron, D.W., and Heathcote, J. (2004). CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24, 693-701. Cox, J.C., and Coulter, A.R. (1997). Adjuvants--a classification and review of their modes of action. Vaccine 15, 248-256. De Gregorio, E., Tritto, E., and Rappuoli, R. (2008). Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38, 2068-2071. Dupont, J., Altclas, J., Lepetic, A., Lombardo, M., Vazquez, V., Salgueira, C., Seigelchifer, M., Arndtz, N., Antunez, E., von Eschen, K., et al. (2006). A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 24, 7167-7174. Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S., and Flavell, R.A. (2008). Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126. Foo, D.G., Alonso, S., Chow, V.T., and Poh, C.L. (2007a). Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9, 1299-1306. Foo, D.G., Alonso, S., Phoon, M.C., Ramachandran, N.P., Chow, V.T., and Poh, C.L. (2007b). Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125, 61-68. Fortier, M.E., Kent, S., Ashdown, H., Poole, S., Boksa, P., and Luheshi, G.N. (2004). The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 287, R759-766. Gilbert, G.L., Dickson, K.E., Waters, M.J., Kennett, M.L., Land, S.A., and Sneddon, M. (1988). Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 7, 484-488. Gromeier, M., Bossert, B., Arita, M., Nomoto, A., and Wimmer, E. (1999). Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 73, 958-964. Guy, B. (2007). The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5, 505-517. Hagiwara, A., Tagaya, I., and Yoneyama, T. (1978a). Common antigen between coxsackievirus A 16 and enterovirus 71. Microbiol Immunol 22, 81-88. Hagiwara, A., Tagaya, I., and Yoneyama, T. (1978b). Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology 9, 60-63. Hagiwara, A., Yoneyama, T., Takami, S., and Hashimoto, I. (1984). Genetic and phenotypic characteristics of enterovirus 71 isolates from patients with encephalitis and with hand, foot and mouth disease. Arch Virol 79, 273-283. Hashimoto, I., Hagiwara, A., and Kodama, H. (1978). Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol 56, 257-261. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3, 196-200. Ho, M., Chen, E.R., Hsu, K.H., Twu, S.J., Chen, K.T., Tsai, S.F., Wang, J.R., and Shih, S.R. (1999). An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341, 929-935. Hoatlin, M.E., Kew, O.M., and Renz, M.E. (1987). Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies. J Virol 61, 1442-1447. Hogle, J.M., Chow, M., and Filman, D.J. (1985). Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229, 1358-1365. Horsfall, A.C., Hay, F.C., Soltys, A.J., and Jones, M.G. (1991). Epitope mapping. Immunol Today 12, 211-213. Hsueh, C., Jung, S.M., Shih, S.R., Kuo, T.T., Shieh, W.J., Zaki, S., Lin, T.Y., Chang, L.Y., Ning, H.C., and Yen, D.C. (2000). Acute encephalomyelitis during an outbreak of enterovirus type 71 infection in Taiwan: report of an autopsy case with pathologic, immunofluorescence, and molecular studies. Mod Pathol 13, 1200-1205. Huang, S.W., Hsu, Y.W., Smith, D.J., Kiang, D., Tsai, H.P., Lin, K.H., Wang, S.M., Liu, C.C., Su, I.J., and Wang, J.R. (2009). Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 47, 3653-3662. Huber, S., Polgar, J., Moraska, A., Cunningham, M., Schwimmbeck, P., and Schultheiss, P. (1993). T lymphocyte responses in CVB3-induced murine myocarditis. Scand J Infect Dis Suppl 88, 67-78. Isaacs, A., and Lindenmann, J. (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147, 258-267. Kawai, T., and Akira, S. (2008). Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 1143, 1-20. Kennett, M.L., Birch, C.J., Lewis, F.A., Yung, A.P., Locarnini, S.A., and Gust, I.D. (1974). Enterovirus type 71 infection in Melbourne. Bull World Health Organ 51, 609-615. Lee, J., Chuang, T.H., Redecke, V., She, L., Pitha, P.M., Carson, D.A., Raz, E., and Cottam, H.B. (2003). Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A 100, 6646-6651. Li, H., Nookala, S., and Re, F. (2007). Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178, 5271-5276. Lin, T.Y., Chang, L.Y., Huang, Y.C., Hsu, K.H., Chiu, C.H., and Yang, K.D. (2002). Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91, 632-635. Lin, T.Y., Hsia, S.H., Huang, Y.C., Wu, C.T., and Chang, L.Y. (2003a). Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 36, 269-274. Lin, T.Y., Twu, S.J., Ho, M.S., Chang, L.Y., and Lee, C.Y. (2003b). Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9, 291-293. Liu, M.L., Lee, Y.P., Wang, Y.F., Lei, H.Y., Liu, C.C., Wang, S.M., Su, I.J., Wang, J.R., Yeh, T.M., Chen, S.H., et al. (2005). Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 86, 3263-3269. Lum, L.C., Wong, K.T., Lam, S.K., Chua, K.B., Goh, A.Y., Lim, W.L., Ong, B.B., Paul, G., AbuBakar, S., and Lambert, M. (1998). Fatal enterovirus 71 encephalomyelitis. J Pediatr 133, 795-798. Matsumoto, M., and Seya, T. (2008). TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60, 805-812. McKee, A.S., Munks, M.W., MacLeod, M.K., Fleenor, C.J., Van Rooijen, N., Kappler, J.W., and Marrack, P. (2009). Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183, 4403-4414. McMinn, P.C. (2002). An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26, 91-107. Nagy, G., Takatsy, S., Kukan, E., Mihaly, I., and Domok, I. (1982). Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 71, 217-227. Netea, M.G., Van der Meer, J.W., Sutmuller, R.P., Adema, G.J., and Kullberg, B.J. (2005). From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother 49, 3991-3996. Nishimura, Y., Shimojima, M., Tano, Y., Miyamura, T., Wakita, T., and Shimizu, H. (2009). Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15, 794-797. Oberste, M.S., Maher, K., Kilpatrick, D.R., and Pallansch, M.A. (1999). Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol 73, 1941-1948. Perry, A.K., Chen, G., Zheng, D., Tang, H., and Cheng, G. (2005). The host type I interferon response to viral and bacterial infections. Cell Res 15, 407-422. Pulli, T., Lankinen, H., Roivainen, M., and Hyypia, T. (1998). Antigenic sites of coxsackievirus A9. Virology 240, 202-212. Putnak, J.R., and Phillips, B.A. (1981). Picornaviral structure and assembly. Microbiol Rev 45, 287-315. Reiter, M.J., Testerman, T.L., Miller, R.L., Weeks, C.E., and Tomai, M.A. (1994). Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 55, 234-240. Roivainen, M., Narvanen, A., Korkolainen, M., Huhtala, M.L., and Hovi, T. (1991). Antigenic regions of poliovirus type 3/Sabin capsid proteins recognized by human sera in the peptide scanning technique. Virology 180, 99-107. Rouse, B.T., and Sehrawat, S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 10, 514-526. Rueckert, R.R., Dunker, A.K., and Stoltzfus, C.M. (1969). The structure of mouse-Elberfeld virus: a model. Proc Natl Acad Sci U S A 62, 912-919. Samuda, G.M., Chang, W.K., Yeung, C.Y., and Tang, P.S. (1987). Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J 6, 206-208. Schmidt, N.J., Lennette, E.H., and Ho, H.H. (1974). An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129, 304-309. Scott, J.H., and Schekman, R. (1980). Lyticase: endoglucanase and protease activities that act together in yeast cell lysis. J Bacteriol 142, 414-423. Shih, S.R., Ho, M.S., Lin, K.H., Wu, S.L., Chen, Y.T., Wu, C.N., Lin, T.Y., Chang, L.Y., Tsao, K.C., Ning, H.C., et al. (2000). Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Res 68, 127-136. Shindarov, L.M., Chumakov, M.P., Voroshilova, M.K., Bojinov, S., Vasilenko, S.M., Iordanov, I., Kirov, I.D., Kamenov, E., Leshchinskaya, E.V., Mitov, G., et al. (1979). Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol 23, 284-295. Sidky, Y.A., Borden, E.C., Weeks, C.E., Reiter, M.J., Hatcher, J.F., and Bryan, G.T. (1992). Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 52, 3528-3533. Simons, J., Kutubuddin, M., and Chow, M. (1993). Characterization of poliovirus-specific T lymphocytes in the peripheral blood of Sabin-vaccinated humans. J Virol 67, 1262-1268. Stutz, A., Golenbock, D.T., and Latz, E. (2009). Inflammasomes: too big to miss. J Clin Invest 119, 3502-3511. Tagaya, I., and Tachibana, K. (1975). Epidemic of hand, foot and mouth disease in Japan, 1972-1973: difference in epidemiologic and virologic features from the previous one. Jpn J Med Sci Biol 28, 231-234. Takeuchi, O., and Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820. Vajdy, M., Selby, M., Medina-Selby, A., Coit, D., Hall, J., Tandeske, L., Chien, D., Hu, C., Rosa, D., Singh, M., et al. (2006). Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 87, 2253-2262. van der Sanden, S., van der Avoort, H., Lemey, P., Uslu, G., and Koopmans, M. Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses. J Gen Virol 91, 1949-1958. Wang, Y., Abel, K., Lantz, K., Krieg, A.M., McChesney, M.B., and Miller, C.J. (2005). The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 79, 14355-14370. Wu, C.N., Lin, Y.C., Fann, C., Liao, N.S., Shih, S.R., and Ho, M.S. (2001). Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20, 895-904. Yamayoshi, S., Yamashita, Y., Li, J., Hanagata, N., Minowa, T., Takemura, T., and Koike, S. (2009). Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15, 798-801. Yasuda, K., Richez, C., Uccellini, M.B., Richards, R.J., Bonegio, R.G., Akira, S., Monestier, M., Corley, R.B., Viglianti, G.A., Marshak-Rothstein, A., et al. (2009). Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol 183, 3109-3117. Yu, C.K., Chen, C.C., Chen, C.L., Wang, J.R., Liu, C.C., Yan, J.J., and Su, I.J. (2000). Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7, 523-528. 蔡幸娟 研究腸病毒七十一型的外鞘蛋白抗原性作為腸病毒疫苗開發 碩士論文 國立台灣大學口腔生物科學研究所 (2006) | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47032 | - |
| dc.description.abstract | 腸病毒71型1998年於台灣爆發腸病毒大流行，造成78因感染致死的案例，而受到極大重視，往後幾年台灣也有許多兒童受到感染並且會造成手足口症以及其他神經方面嚴重的併發症。由於腸病毒71型感染有如此高的致死率，並且缺少有效的抗病毒藥物，因此開發疫苗在第一道防線提高體內的免疫反應以抵抗外來病毒的入侵，為一首要的研究目標。腸病毒71型是由四種外鞘蛋白組成，分別為VP1、VP2、VP3與VP4，其中VP0為VP2與VP4的前驅蛋白，目前猜測VP1具有最主要的抗原決定位，但VP2與VP3亦可能具有抗原決定位，故利用大腸桿菌表現VP0、VP1與VP3三種抗原蛋白，以期混合此三種病毒蛋白分子作為疫苗致敏小鼠可以刺激免疫反應發生。本研究中發現，VP0、VP1與VP3此三種蛋白分子混合之分子疫苗在鋁鹽的作用下可以產生較VP1分子疫苗更多的腸病毒專一性抗體；而將鋁鹽混合其他TLR 依賴性配體作為佐劑使用可以進一步產生更強烈的後天性免疫反應；此外TLR依賴性配體也可降低因鋁鹽所造成過高的第二型輔助性Ｔ細胞作用，並降低以鋁鹽作為佐劑可能造成過敏的副作用；然而在中和性試驗中發現，分子疫苗致敏小鼠並無法產生抗腸病毒71型之中和性抗體，此外為了研究混合此三種分子是否可以有效中和抗腸病毒的抗體，我們更利用競爭型的中和性測試將抗病毒血清與VP0、VP1與VP3混合之蛋白分子作用，結果顯示只有去活化的腸病毒具有抑制抗體中和病毒的能力。本研究中發現，腸病毒結構蛋白混合分子可以產生較VP1高的專一性體液與細胞免疫反應，然而蛋白分子卻不具有主要的抗原決定位而無法刺激產生中和性抗體;此外合併使用鋁鹽與poly(I:C)可以作為一良好的佐劑。由於腸病毒71型死菌疫苗具有其風險性，故開發分子疫苗仍然為現行疫苗發展之首要目標。 | zh_TW |
| dc.description.abstract | Because of the high mortality rate of enterovirus 71 (EV71), development of an effective vaccine has become the most important priority in terms of control strategies for prevention. Coat proteins of EV71, VP1-VP3 have been suggested to be the neutralizing epitopes. In this study, mice were immunized with recombinant structural proteins, including VP0, VP1 and VP3, which were expressed by Escherichia coli expression system to produce an effective vaccine for the induction of immunity. The results showed that VP0, VP1 and VP3 protein mixture combined with alum could induce higher EV71-specific humoral and cellular immunity than VP1 combined with alum. Combination of subunit vaccine with alum and TLR ligands such as poly(I:C), CpG and imiquimod can induce a stronger immune response against viral infection. Furthermore, TLR ligands could reduce the Th2 response which was induced by alum. However, immunization of subunit vaccine could not produce neutralizing antibody. Pre-incubation of VP0, VP1 and VP3 protein mixture with anti-virus serum, then applied to neutralization test, also did not inhibit the ability of neutralization of anti-virus serum. Maybe the proteins expressed from E.coli system did not have a good neutralizing epitope. In conclusion, EV71 subunit mixture had a higher immunogenicity than VP1 alone but could not produce effective neutralizing Ab. Poly(I:C) can serve a good adjuvant for EV71 subunit vaccination. Based on this study, the development of effective subunit vaccine for the prevention of EV71 infection is still an important issue. We believe the study might shed the light on further developing effective immunity and also understanding the immune response against EV71 infection. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T05:45:43Z (GMT). No. of bitstreams: 1 ntu-99-R97449013-1.pdf: 1337596 bytes, checksum: 375503a8040ec001427ca6775f59ad54 (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 口試委員會審定書
誌謝…………………………………………………………………...………...……......I 英文摘要……………………………………………………………..…………….........II 中文摘要……………………………………………………….………………………IV Contents……………………………………………………………….………………..V Chapter I. General Introductio 1.1 Introduction of Enterovirus 71.………………………………..….……….............2 1.1.1Epidemiology of Entrovirus 71…………………………...……………………2 1.1.2 Clinical symptoms of Entrovirus 71 infection…………………………………4 1.1.3 Classification of Enterovirus 71…………………………...…………………..5 1.1.4 Structure and properties of Entrovirus 71……………………………………...6 1.1.5 Antigenic determinants of Entrovirus 71………………………...…………….7 1.1.6 Study on entrovirus 71 vaccine and application……………………...………..9 1.2 Introduction of vaccine adjuvant………………………………..….……..……..11 1.2.1 General introduction of vaccine adjuvant…………………….…..…………..11 1.2.2 Introduction of Toll like receptor ligand…………………….….…..………...12 1.2.3 Introduction of aluminum salts…………………………….……...………….13 1.3 Specific Aims and motives……...…………………………….….….….…………14 Chapter II. Materials and Methods 2.1 Materials………………………….…….………………………………………….17 2.1.1 Vectors…………………………………………………...…………………...17 2.1.2 Animals………………………………………...……………………………..17 2.1.3 Cell lines………………………………………………...……………………17 2.1.4 Broth and plate for Escherichia coli incubation……………...………………17 2.1.5 Medium, buffer and reagents for cell culture………………………...………18 2.1.6 Buffer and Reagents for Western blot………………………………………...19 2.1.7 Reagents for ELISA assay................................................................................20 2.1.8 Buffer for protein purification from E.coli……………………...…………....20 2.1.9 Buffer for EV71 purification by SartobindR Q75X………………...………..21 2.2 Methods…………………………………..…………………...…………………...22 2.2.1 Escherichia coli expression system…………………………...……………...22 2.2.2 Preparation of enterovirus 71……………………………………...…………24 2.2.3 Confirmation of the purified structural protein and EV71 virus…………......26 2.2.4 Immunization of animal model……………………………………………….27 2.2.5 Assay of immune response………………………………...…………………27 2.2.6 Statistical Analysis……………………………………………………………33 Chapter III. Results 3.1 Confirmation of pET28a-VP0, pET28a-VP1 and pET28a-VP3 plasmid………35 3.2 Expression of enteroviral structural proteins by Escherichia coli……………...35 3.3 Purification of enteroviral structural proteins from E.coli cell lysate……...…..35 3.4 Confirmation of purified EV71 virus by Western Blot…………………………36 3.5 Tissue culture infectious dose 50 (TCID50) of enterovirus 71…………...……36 3.6 Intraperitoneal immunization of Balb/c mice with recombinant proteins…...…37 3.7 Determination of EV71-specific T cell response……………………………….39 3.8 Neutralization test………………………………………………………………40 3.9 Competitive neutralization test…………………………….………...…………41 Chapter IV. Discussion and perspective……………………...……………………...42 Figures………………………………………………………………...….....................51 Reference……………………………………………………...……………………….66 Appendix……………………………………………………………………………….76 | |
| dc.language.iso | en | |
| dc.subject | 抗原決定位 | zh_TW |
| dc.subject | 腸病毒71型 | zh_TW |
| dc.subject | 分子疫苗 | zh_TW |
| dc.subject | 佐劑 | zh_TW |
| dc.subject | enterovirus71 | en |
| dc.subject | neutralizing determinant | en |
| dc.subject | adjuvant | en |
| dc.subject | subunit vaccine | en |
| dc.title | 腸病毒71型次單位疫苗的研發與免疫反應的研究 | zh_TW |
| dc.title | Study on development and effect of recombinant subunits vaccine for type 71 enterovirus | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張鑾英(Luan-Ying Chang),顧家綺(Chia-Chi Ku) | |
| dc.subject.keyword | 腸病毒71型,分子疫苗,佐劑,抗原決定位, | zh_TW |
| dc.subject.keyword | enterovirus71,subunit vaccine,adjuvant,neutralizing determinant, | en |
| dc.relation.page | 91 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2010-08-19 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 免疫學研究所 | zh_TW |
| 顯示於系所單位： | 免疫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 未授權公開取用 | 1.31 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。